Use of csDMARDs was associated with a significantly lower risk of mortality (HR 0.413) after ICU admission in patients with rheumatoid arthritis, while high updated CCI, elevated APACHE II score, and prolonged PT-INR predicted poorer prognosis.
Observational (n=67)
No
In patients with rheumatoid arthritis admitted to the ICU, nonuse of csDMARDs, higher comorbidity burden, elevated APACHE II score, and coagulation abnormalities are significant predictors of short-term mortality.
Effect estimate: HR 0.413 (95% CI 0.190-0.899)
p-value: p=0.0229
BACKGROUND: Patients with rheumatoid arthritis (RA) have high mortality risk and are frequently treated in intensive care units (ICUs). METHODS: This was a retrospective observational study. This study included 67 patients (20 males, 47 females) with RA who were admitted at the ICU of our institution for ≥48 h between January 2008 and December 2017. We analyzed the 30-day mortality of these patients and the investigated prognostic factors in RA patients admitted to our ICU. RESULTS: Upon admission, the median age was 70 (range, 33-96) years, and RA duration was 10 (range, 0-61) years. The 5-year survival after ICU admission was 47%, and 30-day, 90-day, and 1-year mortality rates were 22, 27, and 37%, respectively. The major reasons for ICU admission were cardiovascular complications (24%) and infection (40%) and the most common ICU treatments were mechanical ventilation (69%), renal replacement (25%), and vasopressor (78%). In the 30-day mortality group, infection led to a fatal outcome in most cases (67%), and nonsurvival was associated with a significantly higher glucocorticoid dose, updated Charlson's comorbidity index (CCI), and acute physiology and chronic health evaluation (APACHE) II score. Laboratory data obtained at ICU admission showed that lower platelet number and total protein and higher creatinine and prothrombin time international normalized ratio (PT-INR) indicated significantly poorer prognosis. The multivariate Cox proportional hazard model revealed that nonuse of csDMARDs, high updated CCI, increased APACHE II score, and prolonged PT-INR were associated with a higher risk of mortality after ICU admission. CONCLUSION: Our study demonstrated that the nonuse of csDMARDs, high updated CCI, elevated APACHE II score, and coagulation abnormalities predicted poorer prognosis in RA patients admitted to the ICU.
Fujiwara et al. (Tue,) conducted a observational in Rheumatoid arthritis (n=67). csDMARDs use vs. Nonuse of csDMARDs was evaluated on Mortality after ICU admission (HR 0.413, 95% CI 0.190-0.899, p=0.0229). Use of csDMARDs was associated with a significantly lower risk of mortality (HR 0.413) after ICU admission in patients with rheumatoid arthritis, while high updated CCI, elevated APACHE II score, and prolonged PT-INR predicted poorer prognosis.